|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:actsOn
|
selective serotonin inverse agonist
|
|
gptkbp:approvalYear
|
2016
|
|
gptkbp:approvedBy
|
gptkb:FDA
Parkinson's disease psychosis
|
|
gptkbp:ATCCode
|
N05AX15
|
|
gptkbp:brand
|
Nuplazid
|
|
gptkbp:CASNumber
|
706779-19-3
|
|
gptkbp:contraindication
|
QT prolonging drugs
|
|
gptkbp:developedBy
|
gptkb:Acadia_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
57 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C25H34FN3O2
|
|
gptkbp:hasPatentExpiration
|
2028 (US)
|
|
gptkbp:hasSMILES
|
CC(C)N1CCC(CC1)C2=CC=CC=C2C(=O)N3CCC(CC3)C4=CC=C(C=C4)F
|
|
gptkbp:hasUNII
|
4B6X41759U
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pimavanserin
|
|
gptkbp:isNotAnticholinergic
|
true
|
|
gptkbp:isNotAntihistaminic
|
true
|
|
gptkbp:isNotApprovedIn
|
gptkb:European_Union
|
|
gptkbp:isNotDopaminergic
|
true
|
|
gptkbp:legalStatus
|
prescription only (US)
|
|
gptkbp:mechanismOfAction
|
inverse agonist and antagonist at 5-HT2A receptors
|
|
gptkbp:metabolism
|
gptkb:CYP3A5
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
427.55 g/mol
|
|
gptkbp:pregnancyCategory
|
Not assigned (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL2103887
9952918
DB05316
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
hallucination
constipation
peripheral edema
confusional state
|
|
gptkbp:target
|
gptkb:5-HT2C_receptor
5-HT2A receptor
|
|
gptkbp:bfsParent
|
gptkb:N05AX
gptkb:5-HT2C_receptor
|
|
gptkbp:bfsLayer
|
7
|